Jacobson Pharma (HKSE:02633) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02633 Jacobson Pharma Corp Ltd HKSE:02633
56 GF Score
Price HK$1.04
GF Value HK$0.85
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Jacobson Pharma FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02633
56GF Score
Jacobson Pharma Corp Ltd HKSE:02633
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued. The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85. GuruFocus considers Jacobson Pharma to be Modestly Overvalued.

Key valuation signals for HKSE:02633:

  • FFO:
  • GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobson Pharma Business Description

Address 388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score

Get the complete analysis for HKSE:02633

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.04
Price
HK$0.85
GF Value